Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results
First European hypercare launch site initiated following CE mark approval Initial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological Disease Screening commenced 13 blood grouping reagents approved by the FDA for use with OEM
View HTML
Toggle Summary Quotient Limited to Report First Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands , July 22, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2019, will be released before market open on Monday, August 5, 2019.
View HTML
Toggle Summary Quotient Board Announces Contract Extension of CEO Franz Walt
JERSEY, Channel Islands , July 02, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the Board of Directors’ decision to amend Chief Executive Officer (CEO) Franz Walt’s employment
View HTML
Toggle Summary Quotient Limited Announces the Submission of the Initial SDS Microarray CE mark Filing for MosaiQ™
JERSEY, Channel Islands , July 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the submission of its completed dossier for the CE Mark (Conformité Européenne) of its initial
View HTML
Toggle Summary Quotient Limited to Participate in the Raymond James Life Sciences and MedTech Conference
JERSEY, Channel Islands , June 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the inaugural Raymond James Life Sciences and MedTech Conference on
View HTML
Toggle Summary Quotient Limited Recaps Recent Milestone Achievement and Updates on the Initial Serological Disease Screening CE Mark Submission, planned 2019 US Field Trials and Reports Record Financial Results
CE mark received on the initial Immunohematology microarray in April 2019 2018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to permit commercialization Successful European field trial drives the expectation of CE mark submission for the initial
View HTML
Toggle Summary Quotient Limited to Participate in the Jefferies 2019 Healthcare Conference
JERSEY, Channel Islands , May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:30
View HTML
Toggle Summary Quotient Ltd. Announces FDA Approval of Seven Additional Blood Bank Reagents
JERSEY, Channel Islands , May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), an established, commercial-stage diagnostics company (the Company), today announced the U.S. Food and Drug Administration ( FDA ) has approved the commercialization of seven additional blood bank reagents
View HTML
Toggle Summary Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
JERSEY, Channel Islands , May 14, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2019 will be released before market open on Tuesday, May 28, 2019 .
View HTML
Toggle Summary Quotient Limited Receives European CE Mark for its Initial IH Microarray
JERSEY, Channel Islands , May 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced receipt of the CE Mark (Conformité Européenne) for its initial Immunohematology (IH) Microarray for
View HTML